This is not financial advice and should not be treated as such.
SRNE - By endira
Was an oncology drugs and pain management company but changed to COVID-19 treatment last year. developing a drug to treat COVID patients in ICU for respiratory issues.
FA - Recent news shows some success as patients are discharged from hospital within days after receiving treatment. Moving onto Phase 2 experiments are to begin in other countries and the company is already applying for emergency use. TA - diverging from the 20-day SMA. Oversold from CCI and Stoch. Gap back up to the 20-day SMA. volume lowering while going down. Hoping for the price to drop a little further to get in cheap and ride it back up. Previous history of big swings up in price prior to earnings and good news means a good opportunity for a nice swing play before further news comes in / earnings.